A Non-purine Xanthine Oxidoreductase Inhibitor Reduces Albuminuria in Patients with DKD: A Randomized Controlled Trial.

George L BakrisHidetaka MikamiMasayuki HirataAkihiro NakajimaMichael D Cressman

Published in: Kidney360 (2021)

TMX-049 200 mg reduced albuminuria at 12 weeks in patients with DKD and type 2 diabetes. TMX-049 may exert a renoprotective effect independent of its sUA-lowering effect.

Keyphrases

type diabetes
cardiovascular disease
insulin resistance
glycemic control
uric acid
weight loss